Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Ryan Daniels
WB

Ryan Daniels

William Blair
Wall Street Analyst
★★★★☆
#389
on 13Foresight · ranked by our own returns
70%
Success Rate
+20.8%
Average Return
59 of 84 calls profitable · +44.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 70% of Ryan Daniels's ratings turned a profit when each position was held for 1 year — averaging +20.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

118 Buy 14 Hold 0 Sell
Ryan's Stock Coverage 40 ratings · 2026-11-13
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ALHC
Alignment Healthcare
 Oct 08, 2026 HOLD Strong Buy
+109.7% avg upside
20 analysts
 — -12.9% ·
MCK
McKesson
 Oct 05, 2026 BUY Strong Buy
-20.4% avg upside
29 analysts
 — +17.1% ·
IDXX
Idexx Laboratories
 Oct 02, 2026 BUY Buy
+30.3% avg upside
19 analysts
 — +33.6% ·
PHR
Phreesia
 Oct 02, 2026 BUY Strong Buy
+36.7% avg upside
22 analysts
 — +25.3% ·
TMDX
TransMedics Group
 Oct 02, 2026 BUY Strong Buy
+44.6% avg upside
15 analysts
 — +17.5% ·
OPRX
OptimizeRx
 Oct 02, 2026 BUY Strong Buy
+33.5% avg upside
10 analysts
 — -13.0% ·
WAY
Waystar Holding Corp.
 Sep 15, 2026 BUY Strong Buy
+35.0% avg upside
30 analysts
 — +6.8% ·
LFST
Lifestance Health Group
 Aug 21, 2026 BUY Strong Buy
-8.2% avg upside
15 analysts
 — +17.4% ·
LMRI
Lumexa Imaging Holdings, Inc.
 Aug 12, 2026 BUY Strong Buy
+66.2% avg upside
10 analysts
 — +31.5% ·
CAH
Cardinal Health
 Aug 11, 2026 BUY Strong Buy
-14.3% avg upside
30 analysts
 — +16.0% ·
ASTH
Astrana Health
 Aug 06, 2026 BUY Strong Buy
+53.1% avg upside
17 analysts
 — -6.9% ·
DOCS
Doximity
 Aug 06, 2026 BUY Buy
+11.3% avg upside
28 analysts
 — +63.3% ·
PRVA
Privia Health Group
 Aug 06, 2026 BUY Strong Buy
+48.8% avg upside
26 analysts
 — +11.0% ·
HCAT
Health Catalyst
 Aug 06, 2026 BUY Buy
+223.1% avg upside
15 analysts
 — -38.1% ·
EVH
Evolent Health
 Aug 06, 2026 BUY Strong Buy
+125.9% avg upside
19 analysts
 — +31.8% ·
AGL
Agilon Health
 Aug 05, 2026 HOLD Buy
-17.9% avg upside
26 analysts
 — +2.3% ·
COR
Cencora
 Aug 05, 2026 HOLD Buy
-2.6% avg upside
45 analysts
 — +9.2% ·
HNGE
Hinge Health, Inc. Class A
 Aug 04, 2026 BUY Strong Buy
-8.2% avg upside
19 analysts
 — +52.1% ·
MD
Pediatrix Medical Group
 Aug 04, 2026 BUY Hold
-24.6% avg upside
14 analysts
 — +27.4% ·
HSTM
HealthStream
 Aug 03, 2026 BUY Buy
-2.8% avg upside
9 analysts
 — +2.1% ·
TDOC
Teladoc
 Jul 29, 2026 HOLD Buy
+241.7% avg upside
38 analysts
 — -3.7% ·
HCSG
Healthcare Services
 Jul 22, 2026 BUY Buy
+1.6% avg upside
13 analysts
 — +5.2% ·
ADUS
Addus Homecare
 Dec 01, 2025 BUY Strong Buy
+2.4% avg upside
19 analysts
 — +4.1% ·
DH
Definitive Healthcare Corp
 Nov 07, 2025 BUY Hold
+372.6% avg upside
19 analysts
 — -60.8% ·
USPH
US Physical Therapy
 Nov 05, 2025 HOLD Strong Buy
+7.9% avg upside
12 analysts
 — +13.2% ·
INNV
InnovAge Holding
 Nov 05, 2025 HOLD Hold
-8.8% avg upside
12 analysts
 — +127.8% ·
EHC
Encompass Health
 Nov 03, 2025 BUY Strong Buy
-11.5% avg upside
23 analysts
 — +17.0% ·
PIII
P3 Health Partners
 Aug 29, 2025 HOLD Buy
+2149.4% avg upside
8 analysts
 — +10.7% ·
AFIB
Acutus Medical
 Mar 19, 2021 HOLD Sell
+619900.0% avg upside
5 analysts
 — · ·
EW
Edwards Lifesciences
 Dec 18, 2018 BUY Strong Buy
+10.0% avg upside
35 analysts
 — +51.0% ·
PODD
Insulet
 Sep 26, 2018 BUY Strong Buy
+40.0% avg upside
32 analysts
 — +55.2% ·
RMD
Resmed
 Sep 26, 2018 BUY Buy
+4.6% avg upside
27 analysts
 — +18.1% ·
MDT
Medtronic
 Sep 26, 2018 HOLD Buy
+4.4% avg upside
38 analysts
 — +10.7% ·
MEDP
Medpace Holdings
 Aug 17, 2018 BUY Buy
-17.3% avg upside
18 analysts
 — +36.6% ·
THC
Tenet Healthcare
 Jan 23, 2018 HOLD Strong Buy
-9.6% avg upside
29 analysts
 — +15.8% ·
HCA
HCA Healthcare
 Jan 23, 2018 HOLD Strong Buy
-11.8% avg upside
37 analysts
 — +47.6% ·
AKTX
Akari Therapeutics
 Sep 27, 2017 BUY Strong Buy
+865.3% avg upside
8 analysts
 — · ·
ARWR
Arrowhead Pharmaceuticals
 Sep 27, 2017 BUY Strong Buy
+26.6% avg upside
29 analysts
 — +381.0% ·
ILMN
Illumina
 Aug 29, 2017 BUY Buy
-10.1% avg upside
32 analysts
 — +79.0% ·
QDEL
QuidelOrtho
 Jul 28, 2017 BUY Strong Buy
+195.9% avg upside
13 analysts
 — +103.4% ·
🔒 35 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Ryan Daniels — Frequently Asked Questions
How accurate are Ryan Daniels's stock ratings?
Based on the calls 13Foresight could measure, about 70% of Ryan's ratings were profitable over a one-year hold, with an average return of +20.8% per rating, or +44.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Ryan ranked on 13Foresight?
Ryan Daniels is currently ranked #389 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Ryan cover?
Ryan most recently has ratings on ALHC, MCK, IDXX, PHR, TMDX, OPRX, WAY, LFST, LMRI, CAH, ASTH, DOCS and 28 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.